ABVX
Abivax S.A.
There isn't enough reported data to score ABVX yet.
ABVX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| Unavailable | |
| Unavailable |
There isn't enough reported data to rate ABVX's fundamentals.
ABVX PE Valuation
ABVX has no meaningful PE right now: it lost money over the past year.
ABVX Forward outlook
There aren't enough analyst estimates for ABVX to show an outlook.
ABVX Earnings Per Share
ABVX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2023 | $2.6M | +3.5% |
| Q2 2023 | $2.5M | +0.9% |
| Q4 2018 | $358.8K | -8.2% |
| Q2 2018 | $546.6K | +12199% |
| Q4 2017 | $391K | +2414% |
| Q2 2017 | $4.4K | -97% |
| Q2 2016 | $152.2K | -56% |
ABVX's revenue has slid since its 2023 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2023 | -3975% | N/A |
| Q2 2023 | -1759% | N/A |
| Q4 2022 | -1726% | N/A |
| Q2 2022 | -836% | N/A |
| Q4 2018 | -3264% | +51157 points |
| Q2 2018 | -1741% | +6009 points |
| Q4 2017 | -1916% | N/A |
| Q2 2017 | -185150% | -182535 points |
ABVX's operating margin was −3975% last quarter, down 711 points from the same quarter a year ago.
ABVX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$57.9M | -$20.8M |
| Q4 2025 | -$79.2M | -$42.2M |
| Q2 2025 | -$37.1M | +$19.2M |
| Q4 2024 | -$37M | +$42.2M |
| Q2 2024 | -$56.3M | -$24.1M |
| Q4 2023 | -$79.2M | -$30.6M |
| Q2 2023 | -$32.2M | -$3.5M |
| Q4 2022 | -$48.6M | -$22.6M |
ABVX has burned cash in almost every quarter: −$211M over the past year, against −$216M the year before.
ABVX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +15% | +10.1M shares |
| 1 year | +27% | +16.7M shares |
| 3 years | +552% | +67.4M shares |
| 5 years | +725% | +70M shares |
| Available history | +759% | +70.4M shares |
ABVX has 80M diluted shares, up 27% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q4 2025 | — |
| Q2 2025 | — |
| Q4 2024 | — |
| Q2 2024 | — |
| Q4 2023 | — |
| Q2 2023 | — |
| Q4 2022 | — |
ABVX Net Leverage
ABVX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ABVX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.0 | Neutral |
| Stochastic | 7.8 | Oversold |
ABVX's weekly RSI is 41 (neutral) and its Stochastic is 8 (oversold).
ABVX PE vs Healthcare Sector
ABVX has no meaningful PE right now: it lost money over the past year.
ABVX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $88.8 | 1.5% above |
| 20 week MA | $110.0 | 18% below |
| 50 week MA | $114.4 | 21% below |
| 100 week MA | $76.3 | 18% above |
ABVX's trend is mixed: it's above two of its four weekly moving averages, and 18% above its 100-week average.
ABVX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $8.30 | $10.7 | +29% |
| 2024 | $10.7 | $7.12 | -33% |
| 2025 | $7.12 | $142.3 | +1899% |
| 2026 YTD | $142.3 | $90.2 | -37% |
ABVX is down 37% so far in 2026, after finishing higher in two of the previous three years.